Real-World Ustekinumab Experience in Ileum-Dominant Versus Colonic Crohn’s Disease
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Crohn’s disease (CD) presents with diverse phenotypes. It remains unclear if CD location affects therapy efficacy. The aim of this study was to compare the real-world performance of ustekinumab in ileum-dominant and colonic CD. Methods We performed a single-center, IRB-approved, retrospective review of all adult CD patients who received ustekinumab. We stratified patients by ileal involvement: ileum-dominant (ileal and ileocolonic) and colonic CD. The primary outcome was the absence of ulcers on follow-up colonoscopy. The secondary outcomes included CRP, calprotectin, surgery, and hospitalization. Chi-square tests (or Fisher’s exact test) and 2-sample t-tests (or Wilcoxon’s rank-sum test) were used to compare categorical and numeric variables between groups, respectively; analyses were performed using R Computing Software versions 3.6.1. Results Eighty-four patients with ileum-dominant CD and 27 patients with colonic CD were treated with ustekinumab. The median time to follow-up endoscopy was 13 months. Follow-up colonoscopy after ustekinumab therapy was ulcer-free in 45% of ileum-dominant CD and 76% of colonic CD (P = .02). Of patients with ulcers prior to starting ustekinumab, 24% of ileum-dominant CD and 67% of colonic CD were ulcer-free (P = .01). There were similar rates of hospitalizations and surgery and no significant differences in mean calprotectin and CRP between the two groups on follow-up after ustekinumab therapy. Conclusions This real-world experience of ustekinumab demonstrates higher rates of endoscopic healing among colonic CD when compared to ileum-dominant CD. Disease location may predict endoscopic healing by ustekinumab. Further studies are necessary to expand our understanding of ustekinumab responsiveness to different CD phenotypes.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Real-World Ustekinumab Experience in Ileum-Dominant Versus Colonic Crohn’s Disease
- Date Crossref
- 01/10/2024
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of California Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University of Arizona Division of Gastroenterology pays non établi dans la noticeUniversité ou école supérieure
-
University of Phoenix pays non établi dans la noticeUniversité ou école supérieure
-
Banner - University Medical Center Phoenix Division of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
University of Arizona College of Medicine- Phoenix pays non établi dans la noticeUniversité ou école supérieure
-
Phoenix College pays non établi dans la noticeUniversité ou école supérieure
-
Marin Endocrine Care and Research pays non établi dans la noticeÉtablissement de santé
-
Division of Gastroenterology pays non établi dans la noticeInstitution
-
School of Medicine Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
Department of Internal Medicine — University of California, Division of Gastroenterology — University of Arizona et University of Phoenix, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.